Sodium-glucose cotransporter 2 inhibitors (SGLT2i, also called gliflozins or flozins) are one of the newly developed oral anti-hyperglycemic agents used to treat the type 2 diabetes mellitus (Chao and Henry 2010; Heise et al. 2013). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.